What is Vitamin K2?
Vitamin K2 belongs to the menaquinone family and is structurally distinct from Vitamin K1 (phylloquinone from leafy greens), which is primarily used for blood clotting in the liver.
K2 has a different role: It activates two key proteins responsible for calcium distribution throughout the body:
- Osteocalcin: Binds calcium into the bone matrix — activated through K2-dependent carboxylation
- Matrix Gla Protein (MGP): Inhibits calcium deposition in arteries and soft tissues
The principle is straightforward: Without sufficient K2, calcium accumulates in the wrong places—in artery walls instead of bone. K2 directs calcium to where it belongs.
MK-4 vs. MK-7: A Critical Distinction
| Form | Source | Half-life | Bioavailability |
|---|---|---|---|
| MK-4 | Animal meat, butter, eggs | ~1–2 hours | Low, short duration |
| MK-7 | Natto (fermented soybeans), supplements | ~72 hours | High, sustained |
MK-7 is the superior supplemental form: It targets bone and arterial tissues more efficiently and has a three-fold longer half-life than MK-4. Most clinical studies have used MK-7.
What Does the Evidence Really Show?
Strong Epidemiological Foundation
The Rotterdam Study (n=4,807) found that the highest menaquinone intake was associated with 41% lower coronary heart disease and 57% lower cardiovascular mortality compared to the lowest intake. This finding has been confirmed in additional observational cohorts like the Prospect-EPIC study, establishing a solid epidemiological link between dietary K2 and cardiovascular protection.
However, epidemiological studies cannot prove causation—they only show correlation. Confounding factors (such as overall diet quality or lifestyle) could partially explain the association.
Randomized Controlled Trial Evidence
Arterial Stiffness: A landmark 3-year RCT by Knapen et al. (n=244) supplemented postmenopausal women with 180 µg MK-7 daily and found a significant slowing of age-related arterial stiffness progression compared to placebo. Osteocalcin carboxylation—a marker of K2 activity—correlated with the improvements observed.
Bone Density: Multiple RCTs document that MK-7 supplementation reduces bone loss in postmenopausal women. The same Knapen study showed clinically meaningful improvements in bone mineral density and bone strength over 3 years versus placebo.
Biomarkers: Osteocalcin and MGP carboxylation are well-studied and consistently improve with K2 supplementation, confirming the biochemical mechanism works in humans.
The Limitation: Missing Endpoint Data
Despite these promising intermediate findings, no large RCT has yet demonstrated that K2 supplementation actually prevents heart attacks, strokes, or fractures. The VitaK-CAC trial, currently underway, aims to address this gap by measuring coronary artery calcification as a hard outcome.
This is a crucial distinction: We know K2 works at the molecular level and improves surrogate markers (arterial stiffness, bone density), but direct clinical benefit in reducing disease events remains to be proven.
The D3+K2 Synergy Question
Vitamin D3 enhances calcium absorption from the intestines. Vitamin K2 is often positioned as a calcium-metabolism cofactor in this context, leading to popular D3+K2 combinations. The theoretical rationale is sound—D3 mobilizes calcium, while K2 directs it appropriately—but direct evidence that the combination is superior to either alone is limited. Many practitioners recommend them together on mechanistic grounds, even if endpoint data is sparse.
Dosing and Bioavailability
Dietary sources of K2 are limited. Natto (fermented soybeans) contains approximately 100–300 µg per serving but is not widely consumed outside Japan. Cheese and cured meats contain smaller amounts (MK-4 and MK-7 depending on fermentation method).
Most supplemental forms use MK-7 derived from natto fermentation, typically dosed between 90–180 µg daily. The 72-hour half-life means daily dosing is not strictly necessary (some protocols dose 3x weekly or even weekly), but daily administration is more common in studies.
Absorption is fat-soluble, so taking K2 with meals—particularly those containing fat—enhances bioavailability.
Safety and Interactions
Vitamin K2 is likely safe at supplemental doses, with no documented toxicity and no risk from dietary sources.
Critical interaction: All forms of Vitamin K interact with warfarin (Coumadin/Marcumar) and other vitamin K antagonists. If you take warfarin, inform your physician before starting K2—the medication dose may need adjustment to maintain INR stability. Modern anticoagulants (DOACs like apixaban, dabigatran) are not affected by dietary K2 changes.
Possible interactions: Antibiotics that eliminate gut bacteria may reduce K2 production by the microbiome, though supplemental K2 bypasses this concern.
The Bottom Line
Vitamin K2 (especially MK-7) has solid mechanistic evidence and benefits bone and arterial markers in clinical studies. Epidemiological data suggests a protective cardiovascular association. However, we still lack definitive proof that supplementation prevents heart disease or fractures in randomized trials.
For postmenopausal women concerned about bone health or those taking Vitamin D3, a case can be made for K2 supplementation—particularly as part of a comprehensive approach that includes resistance training and adequate calcium intake. For cardiovascular protection, the evidence is more speculative: reasonable on mechanistic grounds, but not yet proven in outcome trials.